Barely Significant
← all excerpts

Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment.

Cancer Chemother Pharmacol · 2024 · PMC11671551 · PMID 39724407

Europe PMCDOI
1
hedged sentence
0.0470
closest p · 0.9× alpha
0.0470
boldest claim

The sentences

a decreasing trendp = 0.047actually significant
Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073).

also in 29,525 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.